2/2/2023 0 Comments Sdt 1.21.1b modding![]() ![]() The number of critically ill patients with MODS and a sinus rhythm of at least 90 beats/min that experienced a heart rate reduction of at least 10 beats/min following oral ivabradine treatment did not differ significantly between groups. No differences in secondary outcomes were observed. ![]() After 96 h, the daily median heart rate was reduced by 7 beats/min in the control group and by 16 beats/min in the ivabradine group (p = 0.014). There were no significant differences in the primary outcome between the ivabradine and control groups (p = 0.147). Secondary outcomes included the effect of ivabradine on hemodynamics, disease severity, vasopressor use, mortality, and adverse events. The primary outcome was the percentage of patients with a heart rate reduction of at least 10 beats/min after 96 h. In this prospective, controlled, randomized, open-label, two-arm phase II trial, seventy patients with MODS, a sinus rhythm of at least 90 beats/min, and contraindications to β-blocker therapy were randomly assigned to receive the standard treatment ± ivabradine (5 mg twice daily) for 96 h via the enteral route. We sought to investigate the effect of the pacemaker current (If) inhibitor ivabradine on heart rate, hemodynamics, and disease severity among patients with MODS. A heart rate higher than 90 beats/min indicates an unfavorable prognosis for patients with multiple organ dysfunction syndrome (MODS). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |